eTheRNA intends to build high-value strategic collaborations for exploring the benefits of the TriMix technology in various disease areas.
eTheRNA seeks collaborative partnerships with pharma companies that enable us to develop - and ultimately also to commercialize - differentiated TriMix-based immunotherapies on either a risk-sharing or out-licensing basis.
mRNA Production Partnering
eTheRNA operates a cGMP accredited mRNA production facility in Niel, Belgium and currently focusses on producing mRNA-constructs exclusively for its own development plans. However as the clinical development program advances, the Company has the option to expand capacity and explore strategic partnerships.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.